Advances in chronic kidney disease
-
Adv Chronic Kidney Dis · May 2011
ReviewIodinated contrast media and the role of renal replacement therapy.
Iodinated contrast media are among the most commonly used pharmacologic agents in medicine. Although generally highly safe, iodinated contrast media are associated with several adverse effects, most significantly the risk of acute kidney injury, particularly in patients with underlying renal dysfunction. ⋯ This has led to research into the capacity for renal replacement therapies to prevent certain adverse effects of iodinated contrast. This review examines the molecular and pharmacokinetic characteristics of iodinated contrast media and critically analyzes data from past studies on the role of renal replacement therapy to prevent adverse effects of these diagnostic agents.
-
Adv Chronic Kidney Dis · May 2011
ReviewNephrogenic systemic fibrosis and gadolinium-based contrast agents.
The strong association between nephrogenic systemic fibrosis (NSF) and exposure to gadolinium-based contrast agents (GBCAs) has greatly affected the care of patients with kidney disease. NSF has been reported in patients with ESRD, CKD, and acute kidney injury (AKI). The majority of cases have occurred in patients with ESRD, but about 20% have been reported in patients with AKI or CKD stages 4 and 5. ⋯ However, this is not the current recommendation for CKD stages 4 and 5, especially with suspected lower risk of noncontraindicated agents. Individualized assessment is important and especially in those patients close to dialysis initiation. Instituting policies is important to address the imaging needs of patients with CKD and AKI while ensuring a balance between benefits and risks.
-
Adv Chronic Kidney Dis · Jul 2009
ReviewRenal replacement therapy in the liver transplant candidate.
Since the implementation of the model of end-stage liver disease score to prioritize patients for orthotopic liver transplantation (OLT), the number of liver transplant candidates with renal failure and on renal replacement therapy (RRT) has dramatically increased. This review is intended to discuss the indications and implications of RRT initiation, the different RRT modalities, and special problems encountered with RRT in OLT candidates.
-
Adv Chronic Kidney Dis · Mar 2009
ReviewIntravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Patients with chronic kidney disease (CKD), especially those requiring maintenance hemodialysis treatments, may lose up to 3 g of iron each year because of frequent blood losses. Higher doses of erythropoiesis-stimulating agents (ESAs) may worsen iron depletion and lead to an increased platelet count (thrombocytosis), ESA hyporesponsiveness, and hemoglobin variability. Hence, ESA therapy requires concurrent iron supplementation. ⋯ Iron and anemia indices have different mortality predictabilities, in that high serum ferritin but low iron, TIBC, and TSAT levels are associated with increased mortality, whereas hemoglobin exhibits a U-shaped risk for death. The increased mortality associated with targeting hemoglobin above 13 g/dL may result from iron depletion-associated thrombocytosis. Intravenous (IV) iron administration may not only decrease hemoglobin variability and ESA hyporesponsiveness, it may also reduce the greater mortality associated with the much higher ESA doses that have been used in some patients when targeting higher hemoglobin levels.
-
Adv Chronic Kidney Dis · Jan 2009
ReviewImaging in diagnosis, treatment, and follow-up of stone patients.
Imaging has an essential role in the diagnosis, management, and follow-up of patients with stone disease. A variety of imaging modalities are available to the practicing urologist, including conventional radiography (KUB), intravenous urography (IVU), ultrasound (US), magnetic resonance urography, and computed tomography (CT) scans, each with its advantages and limitations. Traditionally, IVU was considered the gold standard for diagnosing renal calculi, but this modality has largely been replaced by unenhanced spiral CT scans at most centers. ⋯ Patients with asymptomatic calyceal stones who prefer an observational approach should have a yearly KUB to monitor progression of stone burden. Current research has been aimed toward the development of a micro-CT scan and coherent-scatter analysis to determine stone composition in vivo. This may have a significant impact on the future clinical management of renal calculi by facilitating selection of the most appropriate surgical intervention based on stone composition at the time of presentation.